Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal titleJournal of obesity and weight-loss medication
MetadataShow full item record
AbstractGlucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control and cardiometabolic risk factors in adults with type 2 diabetes mellitus, but pediatric data is sparse.
This is the first report to describe the effects of GLP-1 receptor agonist Exenatide on metabolic risk and weight in adolescents with morbid obesity (BMI>35kg/m) and type 2 diabetes in the first 6 months after treatment initiation. Two patients with morbid obesity who failed conventional therapy with insulin glargine and Metformin were treated with the addition of Exenatide. Metabolic parameters were obtained at 3 and 6 months post intervention.
Improvements in cardiometabolic risk factors, such as fasting glucose and triglyceride levels, as well as HbA1c, were reached at 6 months compared to baseline.
Our cases highlight the therapeutic potential of exenatide for adolescent patients with morbid obesity and type 2 diabetes.
CitationCensani M, Chin VL, Fennoy I. Exenatide Effects on Cardiometabolic Risk and Weight in Adolescents with Morbid Obesity and Type 2 Diabetes Mellitus: Two Case Reports. J Obes Weight Loss Medicat. 2015;1(1):004. doi: 10.23937/2572-4010.1510004. Epub 2015 May 6. PMID: 27182560; PMCID: PMC4864000.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
- Authors: Deacon CF, Mannucci E, Ahrén B
- Issue date: 2012 Aug
- Comparison of Glycemic Variability in Chinese T2DM Patients Treated with Exenatide or Insulin Glargine: A Randomized Controlled Trial.
- Authors: Yin TT, Bi Y, Li P, Shen SM, Xiong XL, Gao LJ, Jiang C, Wang Y, Feng WH, Zhu DL
- Issue date: 2018 Jun
- Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
- Authors: Stenlid R, Cerenius SY, Wen Q, Aydin BK, Manell H, Chowdhury A, Kristinsson H, Ciba I, Gjessing ES, Mörwald K, Gomahr J, Heu V, Weghuber D, Forslund A, Bergsten P
- Issue date: 2023
- Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
- Authors: Iglesias P, Civantos S, Vega B, Pavón I, Guijarro G, Monereo S
- Issue date: 2015 Mar
- Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.
- Authors: Doggrell SA
- Issue date: 2007 Jan